Patents by Inventor Anthony B. Pinkerton

Anthony B. Pinkerton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11806337
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: November 7, 2023
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
  • Publication number: 20230339872
    Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 26, 2023
    Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
  • Publication number: 20230310423
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 5, 2023
    Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
  • Patent number: 11731986
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: August 22, 2023
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
  • Patent number: 11707462
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: July 25, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
  • Patent number: 11673873
    Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: June 13, 2023
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
  • Publication number: 20230116770
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: July 27, 2022
    Publication date: April 13, 2023
    Inventors: Stephen GARDELL, Anthony B. PINKERTON, Eduard SERGIENKO, Hampton SESSIONS
  • Publication number: 20230102520
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of LMPTP, compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: July 2, 2020
    Publication date: March 30, 2023
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Publication number: 20230037225
    Abstract: Provided herein are agonists of the apelin receptor of Formula (I): for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
    Type: Application
    Filed: May 12, 2022
    Publication date: February 2, 2023
    Inventors: Layton H. SMITH, Anthony B. PINKERTON, Paul HERSHBERGER, Patrick MALONEY, Danielle MCANALLY
  • Publication number: 20230029557
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: June 8, 2021
    Publication date: February 2, 2023
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Publication number: 20230026313
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Application
    Filed: August 29, 2022
    Publication date: January 26, 2023
    Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
  • Publication number: 20220402908
    Abstract: Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.
    Type: Application
    Filed: July 7, 2020
    Publication date: December 22, 2022
    Inventors: Satyamaheshwar PEDDIBHOTLA, Paul M. HERSHBERGER, Richard Jason KIRBY, Siobhan MALANY, Layton H. SMITH, Patrick R. MALONEY, Hampton SESSIONS, Daniela DIVLIANSKA, Anthony B. PINKERTON
  • Patent number: 11452717
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 27, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
  • Patent number: 11345705
    Abstract: Provided herein are agonists of the apelin receptor of Formula (I): for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: May 31, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
  • Publication number: 20220144784
    Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 12, 2022
    Inventors: Takuya IKEDA, Yoshiyuki KOBAYASHI, Naoki MIYOSHI, Osamu SUZUKI, Takahiro NAGAYAMA, Takashi TSUJI, Layton H. SMITH, Anthony B. PINKERTON
  • Patent number: 11261164
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: March 1, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20210363142
    Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).
    Type: Application
    Filed: March 22, 2021
    Publication date: November 25, 2021
    Inventors: Anthony B. PINKERTON, Layton H. SMITH
  • Publication number: 20210361636
    Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 25, 2021
    Inventors: Tsuyoshi NAKAMURA, Mayuko AKIU, Takashi TSUJI, Jun TANAKA, Koji TERAYAMA, Mika YOKOYAMA, Anthony B. PINKERTON, Edward Hampton SESSIONS
  • Publication number: 20210355087
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2019
    Publication date: November 18, 2021
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
  • Patent number: 11155525
    Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: October 26, 2021
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Takuya Ikeda, Yoshiyuki Kobayashi, Naoki Miyoshi, Osamu Suzuki, Takahiro Nagayama, Takashi Tsuji, Layton H. Smith, Anthony B. Pinkerton